Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: EW stock price vs AMGN: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at AMGN's multiple
Needs AMGN P/E.
Implied fair value · at EW's multiple
Needs EW P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
11 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Edwards Lifesciences Corporation · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Amgen Inc. · implied price per share
Bear
$98.66
Base
$130.87
Bull
$172.82
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
ABBOTT LABORATORIES
EW vs ABT
JOHNSON & JOHNSON
EW vs JNJ
Medtronic plc
EW vs MDT
BOSTON SCIENTIFIC CORP
EW vs BSX
BAXTER INTERNATIONAL INC
EW vs BAX
DENTSPLY SIRONA Inc.
EW vs XRAY
REGENERON PHARMACEUTICALS, INC.
EW vs REGN
BIOGEN INC.
EW vs BIIB
VERTEX PHARMACEUTICALS INC / MA
EW vs VRTX
Gilead Sciences, Inc.
EW vs GILD
Moderna, Inc.
EW vs MRNA
Eli Lilly and Company
EW vs LLY
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe EW can sustain its 11.5% revenue growth while materially closing the profitability gap versus AMGN, then hold or accumulate selectively; otherwise, the current $88.82 price looks stretched because EW trades at a large premium on P/E, P/S, and EV/EBITDA without superior margin or ROIC support.
EW trades at a clear premium to AMGN on P/E, P/S, EV/EBITDA, and EV/Revenue, yet the model still implies downside to $48.72 from the current $88.82 price. The current price is also above AMGN-implied range and within the upper half of EW's historical band, suggesting valuation is already rich versus AMGN benchmark.
Supporting Metrics
